ASCO GI Archives

Potential new first-line treatment strategy for patients with BRAF V600E-mutant metastatic colorectal cancer

The BREAKWATER open-label, randomized phase 3 study was designed to evaluate first-line treatment with targeted therapies encorafenib and cetuximab plus…

Potentially practice-changing results point to new standard-of -care treatments for patients with metastatic colorectal cancer

Presented today at the ASCO Gastrointestinal Cancers Symposium, 23-25 January in San Francisco, results of 2 phase 3 clinical studies…

First results of the Checkmate 8HW study show first-line dual immunotherapy combination improves outcomes versus standard chemotherapy in metastatic colorectal cancer subtype

Checkmate 8HW is the first phase III study to assess first-line nivolumab plus ipilimumab in patients with unresectable microsatellite instability-high/mismatch…

First targeted radioligand therapy to demonstrate significant and clinically meaningful impact in first-line advanced gastroenteropancreatic neuroendocrine tumors

Results of the multi-center, randomized, comparator-controlled phase III NETTER-2 trial show that first-line treatment with radioligand therapy 177LU-DOTATATE in combination…

Josep Tabernero presents the improvements in survival of patients with metastatic colorectal cancer at ASCO GI Cancers Symposium

The annual ASCO Symposium on Gastrointestinal Cancers took place from 19-21 January. Josep Tabernero, Director of VHIO, presented the results…